Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gepirone vs Placebo in Treatment of Cocaine Dependence - 3

This study has been completed.
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania Identifier:
First received: September 20, 1999
Last updated: March 1, 2013
Last verified: March 2013

The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Gepirone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Gepirone vs Placebo in Treatment of Cocaine Dependence

Further study details as provided by University of Pennsylvania:

Enrollment: 41
Study Start Date: January 1990
Study Completion Date: February 1991
Primary Completion Date: February 1991 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000189

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Principal Investigator: James Cornish, M.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania Identifier: NCT00000189     History of Changes
Other Study ID Numbers: NIDA-00144-3, 3R01DA012268, K20-00144-3
Study First Received: September 20, 1999
Last Updated: March 1, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Anti-Anxiety Agents
Antidepressive Agents
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Receptor Agonists
Therapeutic Uses
Tranquilizing Agents processed this record on November 20, 2014